Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients
NCT00239876 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 140
Last updated 2011-11-02
Summary
This study will evaluate the safety and efficacy of FTY720 combined with tacrolimus and corticosteroids in patients receiving a kidney transplant
Conditions
- Renal Transplantation
Interventions
- DRUG
-
FTY720
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis · Novartis
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-05-31
- Primary Completion
- 2005-12-31
More Related Trials
-
Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant
NCT00099736 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant
NCT00099801 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant
NCT00099749 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Extension Study on the Safety and Efficacy of Enteric-coated Mycophenolate Sodium in Kidney Transplant Recipients
NCT00239070 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients
NCT00229138 ·Status: COMPLETED ·Phase: PHASE4
-
Extension Study of Enteric-coated Mycophenolate Sodium in Combination With Full Dose or Reduced Dose Cyclosporine Microemulsion in Patients With de Novo Kidney Transplants
NCT00238940 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium, After Equimolar Conversion From Mycophenolate Mofetil (MMF), in Patients With Stable Renal Transplant Receiving Tacrolimus
NCT00171392 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Investigate the Tolerability and Safety of Converting Stable Renal Transplant Recipients Who Receive Tacrolimus With or Without Corticosteroids From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS)
NCT00238979 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplantation
NCT00098735 ·Status: COMPLETED ·Phase: PHASE3
-
24 Month Extension to Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients(Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients
NCT00555789 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Tacrolimus Immunosuppressive Therapy After Kidney Transplantation
NCT00717379 ·Status: COMPLETED ·Phase: PHASE4
-
Extension Study on the Efficacy and Safety of Enteric-coated Mycophenolate Sodium Administered in de Novo Kidney Transplant Patients
NCT00239018 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Enteric-coated Mycophenolate Sodium Maintenance Therapy in Patients With Renal Transplant Receiving Cyclosporine Microemulsion and Steroids,
NCT00239057 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Enteric-coated Mycophenolate Sodium and Cyclosporine in Combination With and Without Steroids, in Adult Renal Transplant Recipients
NCT00413920 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant
NCT02118896 ·Status: COMPLETED ·Phase: PHASE3
-
A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation
NCT03995901 ·Status: TERMINATED ·Phase: PHASE3
-
Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant Recipients
NCT00284934 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen in de Novo Renal Transplant Recipients.
NCT00238992 ·Status: COMPLETED ·Phase: PHASE3
-
An Open Label Study to Evaluate the Tolerability and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion (CsA-ME) in Maintenance Renal Transplant Recipients
NCT00239044 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety and Efficacy of FK506E (MR4) in Patients Undergoing Primary Kidney Transplantation
NCT00189839 ·Status: COMPLETED ·Phase: PHASE3
-
Extension Study to Assess Tolerability and Safety of Enteric-coated Mycophenolate Sodium in Renal Transplant Recipients Who Received Mycophenolate Mofetil
NCT00238966 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients
NCT00238953 ·Status: COMPLETED ·Phase: PHASE4
-
Extension Study of Enteric-coated Mycophenolate Sodium With Short-term or no Steroid Use Compared With Enteric-coated Mycophenolate Sodium With Standard Steroid Therapy in de Novo Kidney Recipients
NCT00240955 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate FK778 in Kidney Transplant Patients
NCT00189735 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients
NCT00312143 ·Status: COMPLETED ·Phase: PHASE4